• Today’s Watch List: KeyCorp. (NYSE:KEY), Facebook Inc (NASDAQ:FB), Aeterna Zentaris Inc. (NASDAQ:AEZS), TrueBlue, Inc. (NYSE:TBI), Rite Aid Corporation (NYSE:RAD)

KeyCorp. (NYSE:KEY) belongs to Financial sector. Its net profit margin is 33.90% and weekly performance is 0.20%. On last trading day company shares ended up $15.04. KeyCorp. (NYSE:KEY) distance from 50-day simple moving average (SMA50) is 0.67%. KeyCorp. (NYSE:KEY) announced today that its Board of Directors declared the dividends for the third quarter of 2015. A cash dividend of $0.075 per share on the corporation’s outstanding common shares. The dividend is payable on September 15, 2015 to holders of record of such common shares as of the close of business on September 1, 2015 and A dividend of $1.9375 per share on the corporation’s outstanding 7.750% Non-Cumulative Perpetual Convertible Preferred Stock, Series A, payable on September 15, 2015 to holders of record as of the close of business on August 31, 2015, for the period commencing on (and including) June 15, 2015 to (but excluding) September 15, 2015

Facebook Inc (NASDAQ:FB) belongs to Technology sector. Its net profit margin is 31.30% and weekly performance is 2.91%. On last trading day company shares ended up $90.10. Facebook Inc (NASDAQ:FB) distance from 50-day simple moving average (SMA50) is 9.67%. Senior officials are urging their countrymen to abandon Facebook Inc (NASDAQ:FB) in favor of domestic social media, saying that the latter offer greater freedom of speech, after Mark Zuckerberg’s firm deleted a string of posts containing a slang Russian term for Ukrainians.

On 13 July, Aeterna Zentaris Inc. (NASDAQ:AEZS) shares advanced 0.76% and was closed at $0.24. AEZS EPS growth in last 5 year was 30.40%. Aeterna Zentaris Inc. (NASDAQ:AEZS) year to date (YTD) performance is -60.00%. Aeterna Zentaris Inc. (NASDAQ:AEZS) recently declared that it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. The trial is being conducted in over 120 sites in North America, Europe and Israel. The primary efficacy endpoint is improvement in overall survival.

TrueBlue, Inc. (NYSE:TBI) ended the last trading day at $30.28. Company weekly volatility is calculated as 3.58% and price to cash ratio as 71.35. TrueBlue, Inc. (NYSE:TBI) showed a weekly performance of -0.66%. On July 08, TrueBlue, Inc. (NYSE:TBI) will release 2015 second quarter results Wednesday, July 22, 2015. Management will discuss the results on a live conference call at 2 p.m. Pacific Time (5 p.m. Eastern Time) on Wednesday, July 22, 2015.

Rite Aid Corporation (NYSE:RAD) belongs to Services sector. Its net profit margin is 7.80% and weekly performance is 7.24%. On last trading day company shares ended up $8.89. Rite Aid Corporation (NYSE:RAD) distance from 50-day simple moving average (SMA50) is 5.50%. On July 06, Rite Aid Corporation (NYSE:RAD) announced that Paul Zikmund, a risk management professional with nearly 30 years of experience, is joining Rite Aid as group vice president of risk and controls.

Leave a Reply

Your email address will not be published. Required fields are marked *